References
- Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol. Assess.7(40)iii, ix–x, 1–111 (2003).
- Nicholas R, Chataway J. Multiple sclerosis. Clin. Evid.14(2009), pii: 1202 (2009).
- Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. (4), CD001332 (2003).
- Baker D, Pryce G. The therapeutic potential of cannabis in multiple sclerosis. Expert Opin. Investig. Drugs12, 561–567 (2003).
- Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc.)42, 495–503 (2006).
- Di Marzo V. The endocannabinoid system for the development of new drugs for spasticity. Drugs Future32, 341–351 (2007).
- Sativex® Oromucosal Spray, package insert. GW Pharmaceuticals PLC, Porton Down, UK (2010).
- Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol.18, 1122–1131 (2011).
- Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim. Health Care Res. Dev. doi:10.1017/S1463423612000333 (2012) (Epub ahead of print).
- Gunn H. Risk factors associated with falls in people with multiple sclerosis. Mult. Scler.18, S19 (2012).
- Stenager EN, Jensen B, Stenager M, Stenager K, Stenager E. Suicide attempts in multiple sclerosis. Mult. Scler.17, 1265–1268 (2011).